Ji Soo Park1,2,3, Hong Jae Chon1,2,3,4, Hei-Cheul Jeung5,2, Sang Joon Shin1,2, Sun Young Rha1,2, Joong Bae Ahn1,2, Kang Young Lee6, Nam Kyu Kim6, Hyun Cheol Chung7,8. 1. Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea. 2. Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea. 3. Department of Medicine, Graduate School of Yonsei University, Seoul, Republic of Korea. 4. Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea. 5. Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. 6. Department of Surgery, Colorectal Cancer Center, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. 7. Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea. unchung8@yuhs.ac. 8. Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea. unchung8@yuhs.ac.
Abstract
PURPOSE: We investigated the prognostic factors for recurrence in Korean patients with stage II colon cancer and evaluated their predictive significance with 5-fluorouracil (FU)-based adjuvant chemotherapy. METHODS: We analyzed the relationship between clinicopathological features and relapse-free survival (RFS) of 716 stage II colon cancer patients who underwent curative resection. Predictive values were assessed using 5-year RFS and 5-year cancer-specific survival (CSS). RESULTS: The 5-year RFS, 5-year CSS, 5-year disease-free survival, and 5-year overall survival rates were 87.4, 94.9, 84.8, and 90.5 %, respectively. T4 stage (hazard ratio [HR], 2.342; 95 % confidence interval [CI], 1.348-4.068; p = 0.003), preoperative bowel obstruction or perforation (HR 2.428; 95 % CI 1.241-4.752; p = 0.010), and age older than 70 years (HR 1.740; 95 % CI 1.130-2.678; p = 0.012) were poor prognostic factors for recurrence in multiple Cox regression analyses. In 60 patients with T4 disease, 5-FU-based adjuvant chemotherapy was associated with improved 5-year CSS of the patients (90.3 vs. 46.7 %; HR 0.135; 95 % CI 0.035-0.517; p = 0.003). CONCLUSIONS: We found discordance between the risk factors for recurrence and the predictive value for 5-FU-based adjuvant chemotherapy in Korean patients with stage II colon cancer. Future prospective clinical trials selectively targeting high-risk patients are needed.
PURPOSE: We investigated the prognostic factors for recurrence in Korean patients with stage II colon cancer and evaluated their predictive significance with 5-fluorouracil (FU)-based adjuvant chemotherapy. METHODS: We analyzed the relationship between clinicopathological features and relapse-free survival (RFS) of 716 stage II colon cancerpatients who underwent curative resection. Predictive values were assessed using 5-year RFS and 5-year cancer-specific survival (CSS). RESULTS: The 5-year RFS, 5-year CSS, 5-year disease-free survival, and 5-year overall survival rates were 87.4, 94.9, 84.8, and 90.5 %, respectively. T4 stage (hazard ratio [HR], 2.342; 95 % confidence interval [CI], 1.348-4.068; p = 0.003), preoperative bowel obstruction or perforation (HR 2.428; 95 % CI 1.241-4.752; p = 0.010), and age older than 70 years (HR 1.740; 95 % CI 1.130-2.678; p = 0.012) were poor prognostic factors for recurrence in multiple Cox regression analyses. In 60 patients with T4 disease, 5-FU-based adjuvant chemotherapy was associated with improved 5-year CSS of the patients (90.3 vs. 46.7 %; HR 0.135; 95 % CI 0.035-0.517; p = 0.003). CONCLUSIONS: We found discordance between the risk factors for recurrence and the predictive value for 5-FU-based adjuvant chemotherapy in Korean patients with stage II colon cancer. Future prospective clinical trials selectively targeting high-risk patients are needed.
Entities:
Keywords:
Colon cancer; Predictive factor; Prognostic factor; Stage II
Authors: Kyu-Won Jung; Young-Joo Won; Hyun-Joo Kong; Chang-Mo Oh; Duk Hyoung Lee; Jin Soo Lee Journal: Cancer Res Treat Date: 2014-04-22 Impact factor: 4.679
Authors: M J O'Connell; J A Mailliard; M J Kahn; J S Macdonald; D G Haller; R J Mayer; H S Wieand Journal: J Clin Oncol Date: 1997-01 Impact factor: 44.544
Authors: Chris Twelves; Alfred Wong; Marek P Nowacki; Markus Abt; Howard Burris; Alfredo Carrato; Jim Cassidy; Andrés Cervantes; Jan Fagerberg; Vassilis Georgoulias; Fares Husseini; Duncan Jodrell; Piotr Koralewski; Hendrik Kröning; Jean Maroun; Norbert Marschner; Joseph McKendrick; Marek Pawlicki; Riccardo Rosso; Johannes Schüller; Jean-François Seitz; Borut Stabuc; Jerzy Tujakowski; Guy Van Hazel; Jerzy Zaluski; Werner Scheithauer Journal: N Engl J Med Date: 2005-06-30 Impact factor: 91.245
Authors: Cornelis J A Punt; Marc Buyse; Claus-Henning Köhne; Peter Hohenberger; Roberto Labianca; Hans J Schmoll; Lars Påhlman; Alberto Sobrero; Jean-Yves Douillard Journal: J Natl Cancer Inst Date: 2007-06-27 Impact factor: 13.506
Authors: Michael J O'Connell; Megan E Campbell; Richard M Goldberg; Axel Grothey; Jean-François Seitz; Jacqueline K Benedetti; Thierry André; Daniel G Haller; Daniel J Sargent Journal: J Clin Oncol Date: 2008-05-10 Impact factor: 44.544
Authors: Hak-Mien Quah; Joanne F Chou; Mithat Gonen; Jinru Shia; Deborah Schrag; Ron G Landmann; José G Guillem; Philip B Paty; Larissa K Temple; W Douglas Wong; Martin R Weiser Journal: Dis Colon Rectum Date: 2008-03-06 Impact factor: 4.585